IGC Pharma, Inc. entered into Securities Purchase Agreement and Promissory Note with Vanquish Funding Group Inc. valued at Aggregate principal amount of $238,050 (original issue discount of $31,050), purchase price $207,000 (effective 2026-04-14).
“In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”). Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing VFG with prior written notice.”
Material Agreements
IGC Pharma, Inc. entered into Securities Purchase Agreement and Promissory Note with FirstFire Global Opportunities Fund, LLC valued at Aggregate principal amount of $346,910 (original issue discount of $39,910), purchase price $307,000 (effective 2026-04-14).
“On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice.”
Debt Financings
IGC Pharma, Inc. incurred convertible notes of $238,050 with Vanquish Funding Group Inc. at 12% maturing March 30, 2027.
“In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”). Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing VFG with prior written notice. Solely upon the occurrence and continuation of an Event of Default under each of the Notes, each of VFG and FirstFire has the right, but not the obligation, to convert all or any portion of the outstanding balance of its respective Note — including principal, accrued interest, and any applicable default amounts — into shares (the “Conversion Shares”) of”
Debt Financings
IGC Pharma, Inc. incurred convertible notes of $346,910 with FirstFire Global Opportunities Fund, LLC at 12% maturing April 10, 2027.
“On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora”
Material Agreements
IGC Pharma, Inc. entered into a credit facility with One Deck Capital, Inc. valued at approximately $219,000.
“The Company entered into a loan agreement with One Deck Capital, Inc. (“One Deck”), pursuant to which the Company received approximately $219,000 in financing (the “One Deck Loan”).”
Material Agreements
IGC Pharma, Inc. entered into Promissory Note with Vanquish Funding Group Inc. valued at $353,050 (effective 2026-03-05).
“Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total principal amount of $353,050”
Material Agreements
IGC Pharma, Inc. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. (effective 2026-03-05).
“On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”).”
Debt Financings
IGC Pharma, Inc. incurred loan of approximately $219,000 with One Deck Capital, Inc..
“The Company entered into a loan agreement with One Deck Capital, Inc. (“One Deck”), pursuant to which the Company received approximately $219,000 in financing (the “One Deck Loan”).”
Debt Financings
IGC Pharma, Inc. incurred loan of $353,050 with Vanquish Funding Group Inc. maturing February 28, 2027.
“On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc.”
Material Agreements
IGC Pharma, Inc. entered into 2025 Subscription Agreement with certain investors valued at approximately $234 thousand (effective 2026-01-05).
“entered into a Subscription Agreement (the “2025 Subscription Agreement”) with certain investors named therein (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “Offering”), an aggregate of 779,997 shares of the Company’s common stock”
Governance Changes
IGC Pharma, Inc.: Changed fiscal year-end from March 31 to December 31 (effective 2025-12-31).
“the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.”
Governance Changes
IGC Pharma, Inc.: Amended articles to increase authorized common stock from 150,000,000 to 600,000,000 shares (effective 2025-12-12).
“Effective December 12, 2025, IGC Pharma, Inc. (the “Company”) amended its Amended and Restated Articles of Incorporation in order to give effect to a previously announced increase of its authorized common stock from 150,000,000 shares to 600,000,000 shares.”
M&A Transactions
IGC Pharma, Inc. completed a disposition involving Wellness Essentials Northwest LLC for fair value of approximately $2.7 million (closed 2025-11-13).
“On November 13, 2025, the closing conditions were satisfied and the transactions under the Sale Agreement were consummated for a fair value of approximately $2.7 million.”
Material Agreements
IGC Pharma, Inc. entered into 2024 Share Purchase Agreement with Bradbury Asset Management (Hong Kong) Limited valued at $3,000,000 (effective 2024-03-22).
“On March 22, 2024, IGC Pharma, Inc. (“IGC” or the “Company”) entered into the 2024 Share Purchase Agreement (the “2024 SPA”) with Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) relating to the sale and issuance by our company to the investors of an aggregate of 8,823,529 shares of our common stock, for a total purchase price of $3,000,000”
Material Agreements
IGC Pharma, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at aggregate offering price subject to certain limitations on the amount of Common Stock that may be of (effective 2024-03-19).
“On March 19, 2024, IGC Pharma, Inc. (the “Company”) entered into a new Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”)”
Terry Lierman was appointed as independent Class B director at IGC Pharma, Inc..
“On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.